Table S1. The completeness of the variables for SARS-CoV-2 Delta infections and the at-risk population.
| Variables |
Percentage of infections, %
(n=129) |
Percentage of risk population, %
(n=10,971) |
| Note: “−” means data not available. Abbreviation: SARS-CoV-2=severe acute respiratory syndrome coronavirus 2; COVID-19=coronavirus disease 2019. * The three-dose regimen of a tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 was selected for use in real-world practice. | ||
| Demographic information | ||
| Age | 100 (129/129) | 96.5 (10,586/10,971) |
| Sex | 100 (129/129) | 97.3 (10672/10,971) |
| Vaccination information | ||
| Vaccine manufacturer (1st dose) | 100 (67/67) | 100 (6,724/6,724) |
| Vaccination date (1st dose) | 100 (67/67) | 100 (6,723/6,724) |
| Vaccine manufacturer (2nd dose) | 100 (44/44) | 100 (5,348/5,348) |
| Vaccination date (2nd dose) | 100 (44/44) | 100 (5,348/5,348) |
| Vaccine manufacturer (3rd dose)* | 100 (1/1) | 100 (604/604) |
| Vaccination date (3rd dose) | 100 (1/1) | 100 (604/604) |
| Exposure information | ||
| Exposure start date | 74.4 (96/129) | 56.1 (6,152/10,971) |
| Exposure end date | 80.6 (104/129) | 88.6 (9,716/10,971) |
| Contact type | 100 (129/129) | 92.1 (10,102/10,971) |
| Clinical information | ||
| Date of symptom onset | 83.6 (92/110) | − |
| Date of the first positive sample collection for PCR testing | 100 (129/129) | − |
| Date of the laboratory confirmation | 100 (129/129) | − |
| Clinical severity | 100 (129/129) | − |
| Type of detection | 100 (129/129) | − |